Ivermectin Therapy for Rosacea: Software Platform to Quantify Changes in Erythema and Skin Texture

Download PDF

Introduction: Rosacea’s impact on quality of life comes from both visible and subjective symptoms. Ivermectin 1% cream has demonstrated efficacy and safety as a rosacea therapy, with both anti-inflammatory and acaricidal mechanisms of action. Objectives: Investigate the potential of ivermectin 1% cream to improve rosacea-associated erythema and invisible symptoms by combining established questionnaires with the photography and analysis platform Scarletred® Vision. Materials and Method: Single-center, open-label study of subjects (N=25) with moderate-severe rosacea (erythema, <10 papules/pustules, ≥15 Demodex mites/cm2) treated with ivermectin 1% cream once-daily for ≥16 weeks. Skin symptoms assessed at baseline, week 8 and ≥week 16; erythema assessed by clinician erythema assessment (CEA) and patient self-assessment (PSA); stinging, burning, dryness, itching severity assessed by questionnaire. Standardized digital skin images captured using a smartphone with Scarletred Vision App plus a Scarletred Skin Patch. Standard Erythema Value (SEV) algorithm used to quantify erythema, Gray Level Co-occurrence Matrix to quantify skin texture. Results: At baseline, mean CEA or PSA score was 3.6 with 44% score 3 and 56% score 4; subjects also had severe or moderate subjective symptoms. Ivermectin 1% cream significantly improved CEA and PSA, reduced lesions, and reduced Demodex counts (P<.0001 for all). Stinging, burning, dryness significantly reduced at 16 weeks (P<.0001) as was itching (P<.001). Scarletred Vision showed significant improvement of erythema (P<.0001) and skin roughness (P<.001) at ≥16 weeks, which agreed with CEA and PSA findings. Conclusions: Ivermectin 1% cream was efficacious in treating rosacea papules, pustules, and erythema; reducing Demodex counts, and improving subjective skin symptoms.

Download PDF

Let's get in touch!

Our state of the art digital platform is supplied via flexible SaaS agreement to leading corporates and newcomers worldwide. Connect with us to obtain more information in a personal demo, and to get a scalable solution fitting with your specific clinical study or piloting demands.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Like the publication? Spread the word